Epicardial adipose tissue as target of the incretin-based therapies in cardio-metabolic pathologies: a narrative review
Canadian Journal of Physiology and Pharmacology · 2025
DOI: 10.1139/cjpp-2024-0384 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Canadian Journal of Physiology and Pharmacology, 2025. Verfasst von Andrea S K Pop und 7 weiteren Autor:innen. Beteiligte Einrichtung: Doctoral School Medicine, "Victor Babeș" University of Medicine and Pharmacy of Timișoara, Timișoara, Romania. Hauptthemen laut MEDLINE: Incretins, Adipose Tissue, Pericardium, Cardiovascular Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 100 Literaturangaben. Gefördert von: “Victor Babeș” University of Medicine and Pharmacy of Timișoara, Romania.
Abstract (Originalsprache)
The epicardial adipose tissue (EAT) serves in physiological conditions as a mechanical and thermal myocardial protective layer, as well as a readily available lipid-storage unit. In pathological conditions, EAT expansion becomes deleterious and is currently recognized as an independent risk factor for the progression of cardiovascular diseases. The EAT phenotypic shift from protective to pro-inflammatory/pro-oxidant is facilitated by the presence of metabolic diseases (obesity, metabolic syndrome, and diabetes), which further increase its expansion and dysregulation, favor the occurrence of complications (mainly atrial fibrillation), and promote progression towards heart failure. Glucagon-like peptide-1 (GLP-1) receptor agonists are novel antidiabetic medications belonging to the incretin class that have demonstrated efficacy beyond glycemic control, in terms of weight reduction and cardiorenal protection in patients with type 2 diabetes mellitus. The GLP-1 receptors and glucose-dependent insulinotropic polypeptide (GIP) receptors are expressed in the human EAT and are targeted by an increasing number of pharmacological agonists, with pleiotropic protective effects on EAT structure and function. Herein we review the literature characterizing the benefits of GLP-1 and GIP receptors activation by single and dual agonists with particular emphasis on their effects on EAT and highlight the role of incretin-based therapy for the management of cardiometabolic pathologies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Doctoral School Medicine, "Victor Babeș" University of Medicine and Pharmacy of Timișoara, Timișoara, Romania.
- Centre for Translational Research and Systems Medicine, "Victor Babeș" University of Medicine and Pharmacy of Timișoara, Timișoara, Romania.
- Department of Functional Sciences - Chair of Pathophysiology, "Victor Babeș" University of Medicine and Pharmacy of Timișoara, Timișoara, Romania.
- Institute of Cardiovascular Diseases, Timișoara, Romania.
ORCID-Profile: Maria D Dănilă
Förderung
- “Victor Babeș” University of Medicine and Pharmacy of Timișoara, Romania
Zitieren
APA
Pop, A., Dănilă, M., Giuchici, S., Buriman, D., Lolescu, B., Sturza, A., Muntean, D., & Lascu, A. (2025). Epicardial adipose tissue as target of the incretin-based therapies in cardio-metabolic pathologies: a narrative review. Canadian Journal of Physiology and Pharmacology. https://doi.org/10.1139/cjpp-2024-0384
Vancouver
Pop A, Dănilă M, Giuchici S, Buriman D, Lolescu B, Sturza A, et al. Epicardial adipose tissue as target of the incretin-based therapies in cardio-metabolic pathologies: a narrative review. Canadian Journal of Physiology and Pharmacology. 2025. doi:10.1139/cjpp-2024-0384
BibTeX
@article{Pop2025,
author = {Pop, Andrea S K and Dănilă, Maria D and Giuchici, Silvia and Buriman, Darius G and Lolescu, Bogdan M and Sturza, Adrian and Muntean, Danina M and Lascu, Ana},
title = {Epicardial adipose tissue as target of the incretin-based therapies in cardio-metabolic pathologies: a narrative review},
journal = {Canadian Journal of Physiology and Pharmacology},
year = {2025},
doi = {10.1139/cjpp-2024-0384}
}
EUVIMED